CHICAGO, June 17, 2004 (PRIMEZONE) -- Molecular Diagnostics, Inc. (OTCBB:MCDG) announced today that it will hold an investor conference call at 4:15 p.m. Eastern Daylight Savings Time on Thursday, June 24, 2004. Molecular Diagnostic's President and CEO, Denis M. O'Donnell, M.D., will host the call.
"We are committed to ensuring maximum disclosure of information to our current shareholders and future investors," stated Dr. O'Donnell. "As a result, given the significant number of events which have occurred for Molecular Diagnostics over the past several months, we believe an in-depth discussion of our activities with the investment community is warranted."
Molecular Diagnostics develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, gastrointestinal, and other cancers. The InPath(TM) System is being developed to provide medical practitioners with a highly accurate, low-cost cervical cancer screening system that can be integrated into existing medical models or at the point-of-care.
Interested parties are invited to listen to the conference call by telephone.
Instructions for hearing the conference call are as follows:
To hear the conference call live: Call 1-800-434-1335 in the United States or Canada or; Call 1-404-920-6620 in the Atlanta Area or Internationally Pin Code: 949989 ** Exclusive **: For Expedited Entry into the Conference, please register via this link for your Direct Access 800-number: http://www.accuconference.com/MCDG To hear a recording of the call (available immediately following the call by telephone for 30 days after the call takes place): Call 1-800-977-8002 in the United States or Canada or; Call 1-404-920-6650 in the Atlanta Area or Internationally Pin Code: Press * then 949989
More information is available at: www.Molecular-Dx.com
Certain statements in this release are forward-looking. These statements are based on Molecular Diagnostics' current expectations, intentions, hopes, beliefs or predictions and involve many risks and uncertainties, such as the Company's ability to obtain sufficient financing, the results of clinical trials with respect to the InPath(TM) System, and the success of the Company's product development efforts. Actual results may differ materially from those expressed or implied in such forward-looking statements depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2003 and its Quarterly Report on Form 10-QSB for the quarter ended March 31, 2004. Copies of these filings may be obtained by contacting the company at 414 North Orleans Street, Suite 510, Chicago, IL 60610 or the SEC. Except as expressly required by law, Molecular Diagnostics undertakes no obligation to publicly update or revise any forward-looking statements contained herein.